- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03106090
Studying Survivorship Care Plans in Head and Neck Cancer
14 gennaio 2020 aggiornato da: Duke University
Comparison of Enhanced Survivorship Care Plans in a Head and Neck Cancer Clinic to Standard of Care
The study will focus on survivorship care for head and neck cancer patients cared for within Duke Cancer Center clinics.
Standardized survivorship care plans (sSCP) are being implemented based on the American Society for Clinical Oncology's criteria.
These documents provide a summary of treatment received, and list side effects and follow-up information after cancer treatment.
Taking advantage of this transition, the investigator will study three groups of patients: (a) early survivors treated before the sSCP was implemented, (b) early survivors treated after the sSCP was implemented, and (c) current patients who will receive an individualized enhanced SCP (eSCP), which will include additional information tailored to patient preferences.
The investigators hypothesize that patients receiving enhanced survivorship care plans will increase their knowledge regarding their health care plan and wellness trajectory; increase their ability to identify the symptoms they most likely can expect as a result of their cancer treatment; and be more likely to engage in conversations with their PCP about healthy behaviors and screening guidelines.
Panoramica dello studio
Stato
Terminato
Condizioni
Intervento / Trattamento
Tipo di studio
Interventistico
Iscrizione (Effettivo)
6
Fase
- Non applicabile
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27710
- Duke Health, Duke Cancer Center
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
18 anni e precedenti (Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- Completed treatment for a head or neck cancer at Duke Cancer Center within 4 months of consent OR
- Will complete treatment for a head and neck cancer at Duke Cancer Center within 3 weeks of consent AND
- Able to read and understand English
- Capable of giving informed consent
- Are at least age 18.
Exclusion Criteria:
- incompetent for interview (documented diagnosis of active psychosis or dementia) or unable to provide informed consent as assessed by the interviewer; or too sick to participate, as judged by a member of the research team
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Nessun intervento: No SCP Control
Patients returning for early follow-up who did not receive SCP.
|
|
|
Nessun intervento: SOC SCP Control
Patients returning for early follow-up who received a standard of care SCP.
|
|
|
Sperimentale: eSCP Intervention
Patients currently receiving treatment who will be enrolled to receive an "enhanced" SCP (eSCP) with additional information beyond ASCO guidelines tailored to patient concerns and preferences.
|
The eSCP includes a treatment summary section, a section detailing follow-up and test recommendations, a section on anticipated and potential side effects, as well as additional information specific to their experience/concerns.
They will receive a patient education notebook outlining symptoms and their management that is tailored to those that the subject may be likely to experience during their survivorship care trajectory.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Head and Neck Cancer Survivor Knowledge
Lasso di tempo: 5 minutes to complete 3 months after treatment end
|
Assesses survivor knowledge of potential cancer or treatment-related symptoms and knowledge of healthy behaviors through the use of the Head and Neck Cancer Survivor Knowledge Scale
|
5 minutes to complete 3 months after treatment end
|
|
Change in Head and Neck Cancer Survivor Knowledge
Lasso di tempo: 5 minutes to complete; measured pre-intervention and 3 months after intervention
|
Assesses survivor knowledge of potential cancer or treatment-related symptoms and knowledge of healthy behaviors through the use of the Head and Neck Cancer Survivor Knowledge Scale in intervention group
|
5 minutes to complete; measured pre-intervention and 3 months after intervention
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Distress in head and neck cancer survivors
Lasso di tempo: 5 minutes to complete 3 months after treatment end
|
Assesses risk of distress defined within post-traumatic stress after treatment through the use of the PTSD Checklist
|
5 minutes to complete 3 months after treatment end
|
|
Distress in head and neck cancer survivors
Lasso di tempo: 5 minutes to complete 3 months after treatment end
|
Assesses distress through the use of the NCCN Distress Thermometer
|
5 minutes to complete 3 months after treatment end
|
|
Change in distress for head and neck cancer survivors
Lasso di tempo: 5 minutes to complete; measured pre-intervention and 3 months after intervention
|
Assesses risk of distress defined within post-traumatic stress after treatment through the use of the PTSD Checklist in the intervention group
|
5 minutes to complete; measured pre-intervention and 3 months after intervention
|
|
Change in distress for head and neck cancer survivors
Lasso di tempo: 5 minutes to complete; measured pre-intervention and 3 months after intervention
|
Assesses distress through the use of the NCCN Distress Thermometer in the intervention group
|
5 minutes to complete; measured pre-intervention and 3 months after intervention
|
|
Uncertainty in head and neck cancer survivors
Lasso di tempo: 5 minutes to complete 3 months after treatment end
|
Assesses uncertainty related to presence of symptoms after cancer treatment through the use of the Mishel Uncertainty in Illness Scale -Survivor/Caregiver form
|
5 minutes to complete 3 months after treatment end
|
|
Change in uncertainty in head and neck cancer survivors
Lasso di tempo: 5 minutes to complete; measured pre-intervention and 3 months after intervention
|
Assesses uncertainty related to presence of symptoms after cancer treatment through the use of the Mishel Uncertainty in Illness Scale -Survivor/Caregiver form in the intervention group
|
5 minutes to complete; measured pre-intervention and 3 months after intervention
|
|
Quality of life in head and neck cancer survivors
Lasso di tempo: 5 minutes to complete 3 months after treatment end
|
Assesses quality of life in head and neck cancer patients EORTC Quality of Life Questionnaire Head & Neck (QLQ H&N35)
|
5 minutes to complete 3 months after treatment end
|
|
Change in quality of life in head and neck cancer survivors
Lasso di tempo: 5 minutes to complete; measured pre-intervention and 3 months after intervention
|
Assesses quality of life in head and neck cancer patients EORTC Quality of Life Questionnaire Head & Neck (QLQ H&N35) in the intervention group
|
5 minutes to complete; measured pre-intervention and 3 months after intervention
|
|
Self-efficacy in head and neck cancer survivors
Lasso di tempo: 5 minutes to complete 3 months after treatment end
|
Assesses self-efficacy in cancer patients through the use of the Self-Efficacy Scale
|
5 minutes to complete 3 months after treatment end
|
|
Change in self-efficacy in head and neck cancer survivors
Lasso di tempo: 5 minutes to complete; measured pre-intervention and 3 months after intervention
|
Assesses self-efficacy in cancer patients through the use of the Self-Efficacy Scale
|
5 minutes to complete; measured pre-intervention and 3 months after intervention
|
|
Information processing in head and neck cancer survivors
Lasso di tempo: 5 minutes to complete 3 months after treatment end
|
Assesses information processing in cancer patients through the use of the EORTC QLQ Information Module (QLQ INFO25)
|
5 minutes to complete 3 months after treatment end
|
|
Change in information processing in head and neck cancer survivors
Lasso di tempo: 5 minutes to complete; measured pre-intervention and 3 months after intervention
|
Assesses information processing through the use of the EORTC QLQ Information Module (QLQ INFO25)
|
5 minutes to complete; measured pre-intervention and 3 months after intervention
|
|
Survivorship care plan perceptions in head and neck cancer survivors
Lasso di tempo: 5 minutes to complete 3 months after treatment end
|
Using open ended questions during a qualitative interview, survivors will provide their perception of how survivorship care plans were useful or not in their care
|
5 minutes to complete 3 months after treatment end
|
|
Survivorship needs after treatment completion -- primary care provider documentation
Lasso di tempo: 10 minutes to complete documentation review of 6 months of PCP records
|
Using a documentation checklist developed by the study team, discussions on survivorship needs when returning to clinic will be assessed with a focus on symptom management or incorporation of healthy behaviors to reduce cancer recurrence
|
10 minutes to complete documentation review of 6 months of PCP records
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Investigatori
- Investigatore principale: Deborah H Allen, PhD, RN, Duke Health
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
19 aprile 2017
Completamento primario (Effettivo)
2 gennaio 2020
Completamento dello studio (Effettivo)
2 gennaio 2020
Date di iscrizione allo studio
Primo inviato
29 marzo 2017
Primo inviato che soddisfa i criteri di controllo qualità
4 aprile 2017
Primo Inserito (Effettivo)
10 aprile 2017
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
18 gennaio 2020
Ultimo aggiornamento inviato che soddisfa i criteri QC
14 gennaio 2020
Ultimo verificato
1 gennaio 2020
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- Pro00079937
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
NO
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su educational materials
-
Mohammed V Souissi UniversityCompletato
-
BenQ Materials CorporationCompletato
-
Cairo UniversityCompletatoSclerosi multipla recidivante-remittenteEgitto
-
Xiongjing JiangYinyi(Liaoning) Biotech Co., Ltd.CompletatoIctus ischemico | Stenosi dell'arteria vertebrale
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI)Completato